ContentTitleLinkCategoriesTags
Clinical Breast Cancer 2022Diagnosis of Leptomeningeal Metastasis in Women With Breast Cancer Through Identification of Tumor Cells in Cerebrospinal Fluid Using the CNSide™ AssayCNS Metastases

American Academy of Neurology 2022

Using Cerebrospinal Fluid Tumor Cell (CSF-TC) Assays to Track Disease Burden and Treatment Response in Patients with Leptomeningeal MetastasisCNS Metastases

San Antonio Breast Cancer Symposium 2021

Characterization of HER2 Amplification in the Cerebrospinal Fluid of Patients with Leptomeningeal Disease in Stage IV Patients with Breast CancerBreast Cancer, CNS Metastases

Society for Neuro-Oncology 2021

Case Series of Multi-Institutional Utility of CNSide™ to Manage Leptomeningeal Disease in Patients with Metastatic Breast CancerBreast Cancer, CNS Metastases

SNO Brain Metastases 2021

Beyond Cytology – A Single Institution Experience Using CNSide™ for Diagnosing and Monitoring Treatment Response in Non-Small Cell Lung Cancer with Leptomeningeal Carcinomatosis (LMC)CNS Metastases

Molecular Med Tri-Con 2021

Detection of EGFR Mutations in Quantity Insufficient Tissue Slides by High Sensitivity Assay Target Selector™ in Patients with Non-Small Cell Lung CancerLung Cancer

ASCO 2020

Diagnosis of leptomeningeal metastasis (LM) through identification of circulating tumor cells (CTCs) in cerebrospinal fluid (CSF)Technology Platform

International Association for the Study of Lung Cancer (IASLC) 2020

Utility of Liquid Biopsy in Diagnosis and Treatment Response in EGFR Mutant NSCLC Patients with Leptomeningeal InvolvementLung Cancer

Society for Neuro-Oncology 2020

Target Selector™ cerebrospinal fluid (CSF) circulating tumor cells and biomarker analysis: improving sensitivity and targeted treatment options in breast and NSCLC cancer patients with CNS involvementLung Cancer

San Antonio Breast Cancer Virtual Symposium 2020

HER2 Expression in Matched Metastatic Tumor and Circulating Tumor Cells (CTCs) In Breast Cancer: Implications for profiling and monitoring of HER2 statusBreast Cancer

University of Missouri at Kansas City, Kansas City 2019

Clinical utility of circulating tumor cell (CTC) analysis in patients with metastatic NSCLC receiving first-line chemotherapyLung Cancer

UC San Diego Health System 2019

Surrogate or Not: The Role for Cell Free Circulating DNA in Detecting EGFR Mutations Present in Tumor TissueBiomarkers

PLOS ONE 2019

Analytical validation of the Target Selector ctDNA platform featuring single copy detection sensitivity for clinically actionable EGFR, BRAF, and KRAS mutationsLung Cancer

Clinics in Oncology – Breast Cancer 2019

Clinical Utility of Target Selector™ Circulating Tumor Cell (CTC) Testing in Tumor Marker Gene Amplification and Protein Expression in Metastatic Breast Cancer ManagementBreast Cancer

Clinics in Oncology – General Oncology 2019

Demonstrated Clinical Utility of Target Selector™ ctDNA Testing: Liquid Biopsy EGFR Mutation Detection Enabled Targeted Therapy Selection for Three Advanced NSCLCLung Cancer

AMP 2019

Highly sensitive and specific detection of Cytokeratin Positive and Negative Circulating Tumor CellsTechnology Platform

AMP 2019

Target Selector™ DNA EGFR kit for tissue demonstrates high sensitivity without the need for macro-dissectionBiomarkers

AMP 2019

Mutant-p53 antibody stains cytokeratin negative CTCs enriched and detected with a “Pan-CTC” antibody cocktailBiomarkers

AMP 2019

Detection of Potential Epithelial Mesenchymal Transition Cells in Localized Prostate CancerProstate Cancer

AMP 2019

Monitoring breast cancer biomarkers from circulating tumor DNA using Target Selector™ NGS Breast PanelBreast Cancer

AMP 2019

Validation of Target Selector™ Next Generation Sequencing Lung Panelfor the Detection of Circulating Tumor TNA AlterationsLung Cancer

AACR 2019

Validation of a highly sensitive Target Selector™ ctDNA assay for ESR1 resistance mutations using an NGS enrichment strategyBiomarkers

World Conference in Lung Cancer 2019

The Dynamic Range of Mutant Allele Fraction Detected in Patients with NSCLC: Clinical Experience Data and Clinical ImplicationsLung Cancer

San Antonio Breast Cancer Symposium 2019

Clinical Data in Over 1,500 Patients Across All Stages of Breast Cancer with Target Selector™ Circulating Tumor Cell TechnologyBreast Cancer

Oncology & Hematology Review 2018

Detecting an ALK Rearrangement via Liquid Biopsy Enabled a Targeted Therapy-based Approach for Treating a Patient with Advanced Non-small Cell Lung CancerLung Cancer

Journal of Thoracic Oncology 2018

ROS-1 Rearrangements in Circulating Tumor CellsBiomarkers

Biomarkers Summit 2018

Microfluidic Assay Detects dMMR in Circulating Tumor Cells (CTCs)Biomarkers

AACR-IASLC 2018

Validation of the QuantStudio5 Instrument for Use in Biocept’s TargetSelector™ ctDNA Lung Cancer AssaysTechnology Platform

AACR 2018

TargetSelector™ CTC technology demonstrates clinical utility in monitoring treatment response in germ cell tumors (testicular cancer)Technology Platform

AACR 2018

Validation of Highly Sensitive Target Selector™ ctDNA Assays for EGFR, BRAF, and KRAS MutationsBiomarkers

World Conference in Lung Cancer 2018

Analysis and Monitoring CTCs and ctDNA in CSF Demonstrates Clinical Concordance in Tesevatinib Treated NSCLC Patients with LMLung Cancer

Journal of Thoracic Oncology 2017

Clinical Utility of Plasma EGFR T790M Mutation Detection in Advanced Non-Small Cell Lung Cancer Patients According to RECIST CriteriaLung Cancer

ASCO 2017

Biocept’s Sample Collection for Tumor Cell Analysis Demonstrates Superior PerformanceTechnology Platform

ASCO 2017

Clinical Experience in ctDNA Profiling of NSCLC 2000 Cases Using TargetSelector™ Demonstrates High SensitivityLung Cancer

AACR 2017

A concordance study of the ArcherDx Reveal ctDNA 28 NGS panel and Biocept’s Target-Selector™ mutation assay using ctDNA collected in Biocept’s CEE-sure blood collection tubeTechnology Platform

ESMO 2016

Clinical evaluation of the utility of a liquid biopsy (Circulating tumoral cells and ctDNA) to determine the mutational profile (EGFR, KRAS, ALK, ROS1 and BRAF) in advanced NSCLC patients.Lung Cancer

ASCO 2016

The performance of a comprehensive CTC anti-body capture cocktail in the detection and phenotypic analysis of CTCsTechnology Platform

San Antonio Breast Cancer Symposium 2016

Circulating Tumor Cell (CTC) Biomarker Evaluation from Patients with Metastatic Breast Cancer (MBC) Utilizing the Target Selector™ PlatformBreast Cancer

Clinical Translational Oncology 2015

Correlation of hormone receptor status between circulating tumor cells, primary tumor and metastasis in breast cancer patientsBreast Cancer

ASCO 2015

Clinical validation and utility of a liquid biopsy for non-small cell lung carcinoma utilizing CTCs and ctDNA to analyze ALK, ROS and EGFR statusLung Cancer

AACR 2015

High Sensitivity Detection of Rare EGFR Mutations with ctDNA using Target-Selector™ AssaysBiomarkers

Molecular Assay Development 2015

Validation of PD-L1 Expression on Circulating Tumor Cells in Lung CancerLung Cancer

San Antonio Breast Cancer Symposium 2014

Prospective characterization of HER2-positive circulating tumor cells in patients with HER2- negative metastatic breast cancerBreast Cancer

Cancer Cell 2014

Hematogenous Metastasis of Ovarian Cancer: Rethinking Mode of SpreadOvarian Cancer

Cancer Medicine 2013

Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancerBiomarkers

ASCO 2012

Estrogen receptor and progesterone receptor immunocytochemistry staining in circulating tumor cells as compared to primary tumor or metastatic biopsyBiomarkers

ASCO 2012

Detection of discordant HER2 status by FISH in circulating tumor cells and disseminated tumor cells in early stage breast cancer using a microfluidicbased cell enrichment and extraction platform (OncoCEE™)Biomarkers

ASCO 2012

Mutational analysis of circulating tumor cells in breast cancer patients by targeted clonal sequencingBreast Cancer

AACR 2012

The CEE-Selector™ Assay: A tool for the identification of rare allele variantsTechnology Platform

San Antonio Breast Cancer Symposium 2011

Estrogen receptor and progesterone receptor immunocytochemistry staining in circulating tumor cells as compared to primary tumor or metastatic biopsyBiomarkers

San Antonio Breast Cancer Symposium 2011

Detection of HER2 gene amplification in circulating tumor cells and disseminated tumor cells by fluorescence in situ hybridization using OncoCEE™Biomarkers

Molecular Med Tri-Con 2011

Detection of EpCAM-negative and Cytokeratin-negative Circulating Tumor Cells in Peripheral BloodTechnology Platform

Cancer Genetics 2011

FISH-based determination of HER2 status in circulating tumor cells isolated with the microfluidic CEE™ platformBiomarkers

Cancer Discovery 2011

A Novel Platform for Detection of CK+ and CK- CTCsTechnology Platform

Biomicrofluidics 2011

Efficient capture of circulating tumor cells with a novel immunocytochemical microfluidic deviceTechnology Platform

Biomicrofluidics 2011

Efficient Capture of Suspended Tumor Cells with a Novel Immunocytochemical Microfluidic DeviceTechnology Platform

ASCO 2011

Redefining CTCs: Detection of additional circulating tumor cells using an antibody capture cocktail and HER2 FISHTechnology Platform

ASCO 2011

Detection of HER2 status of circulating tumor cells and disseminated tumor cells using a microfluidic platform (cell enrichment and extraction technology [CEE™])Biomarkers

AACR 2011

Fluorescence labeling of cytokeratin-negative circulating tumor cells in peripheral blood: A new paradigm for the study of cancer progressionTechnology Platform

AACR 2011

Redefining CTCs: Detection of cytokeratin-negative circulating tumor cells (CTCs)Technology Platform

The Journal of Urology 2010

Recovery of Circulating Tumor Cells in Urothelial Carcinoma Cell Lines Utilizing a Novel Antibody Based Microfluidic Cell Capture TechniqueTechnology Platform

San Antonio Breast Cancer Symposium 2010

Detection of circulating tumor cells and HER2 gene amplification status in breast cancer using a novel microfluidic platform (Cell Enrichment and Extraction Technology, CEE™)Biomarkers
CEE™ Cell Enrichment and Extraction Technology Enabling Early, Non-invasive Isolationof Rare Cells for DiagnosticsTechnology Platform
Mouse Models for MEMS (Micro-Electro-Mechanical System) Based Biomarker Discovery: A Novel CTC Mouse-TrapTechnology Platform
Comparison of fluorescence in situ hybridization of estrogen receptor genetic locus with protein expression in invasive breast carcinomaTechnology Platform